2019 American Society of Hematology Annual Meeting*

Download All
December 7-10, 2019; Orlando, Florida
CCO’s expert faculty review and share their expert perspectives on key findings in acute and chronic leukemias presented at the 2019 ASH annual meeting.
Eunice S. Wang, MD

Acute and Chronic Leukemias

Slidesets ECOG-ACRIN E2906: Maintenance Decitabine After Response to Intensive Therapy in Older AML Patients
Slidesets Analysis: Prognostic Effect of Time From Diagnosis to Treatment in Newly Diagnosed AML
Slidesets Phase Ib/II Study: FLAG-IDA Plus Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML
Slidesets First-line Hyper-CVAD Plus Ponatinib in Adults With Ph+ Acute Lymphoblastic Leukemia: Long-term Safety and Efficacy
Slidesets Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Slidesets Interim Phase II Results From AG221-AML-005: Enasidenib + Azacitidine vs Azacitidine Alone in Newly Diagnosed AML With IDH2 Mutations
Slidesets Outcomes in R/R AML After First-line Treatment With Venetoclax Plus a Hypomethylating Agent
Slidesets Updated Analysis of Frontline Dasatinib + Blinatumomab in Patients With Newly Diagnosed Ph+ ALL
Slidesets Phase III Trial of Blinatumomab vs Chemotherapy as Post-Reinduction Therapy for Children and Young Adults With Relapsed B-ALL
Slidesets QUAZAR AML-001: Phase III Study of CC-486 Maintenance Therapy in Patients With Acute Myeloid Leukemia in First Remission

Get expert perspective on the key studies in AML and ALL from ASH 2019 that may impact your practice and help you to improve patient outcomes.

Eunice S. Wang, MD Released: February 3, 2020
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings